Cervical cancer: FIGO 2018 or 2014?
Two women with cervical cancer, both written as "stage III". One has a 3 cm tumor with pelvic nodes on PET. The other has a tumor reaching the pelvic wall and no nodes. Pembrolizumab with chemoradiation is on the table for both. Are they the same stage?
Concepts first
- FIGO
- International Federation of Gynecology and Obstetrics, which writes the cervical cancer staging. FIGO 2018 is still current (confirmed in the 2025 FIGO report).
- FIGO 2014
- The prior system, the same cervix rules as FIGO 2009 (approved in 2008). Trials designed before 2019 kept it: KEYNOTE-A18 enrolled 2020 to 2022 in FIGO 2014. It stages by exam and does not count lymph nodes.
- r and p
- In FIGO 2018, nodes found on imaging are IIIC "r"; nodes proven on pathology are IIIC "p". Isolated tumor cells do not change the stage.
- Parametrium
- The connective tissue beside the cervix, between it and the pelvic wall.
- LVSI
- Lymphovascular space invasion: tumor in small vessels on the biopsy. Prognostic, but it never changes the stage.
How FIGO 2018 assigns the stage.Exam first, then any imaging or pathology available. Pathology overrides imaging and exam. When in doubt, choose the lower stage. The stage is fixed once all results are in, and is not changed at recurrence (Bhatla 2019; 2025 update).
Why the year matters
The trap: IIIC in 2018 is not stage III in 2014.A visible tumor of 4 cm or less confined to the cervix, with pelvic nodes, is FIGO 2018 IIIC1 but FIGO 2014 IB1. KEYNOTE-A18 enrolled FIGO 2014 IB2 to IIB with positive nodes, or III to IVA with any nodes, so that patient was not eligible. Same label, different tumor: FIGO 2014 IB2 is over 4 cm (today's IB3); FIGO 2018 IB2 is 2 to 4 cm. A 3 cm tumor charted as "IB2" was not eligible.
Staging in four questions
Try it: stage calculator
Starts on a 3 cm tumor with pelvic nodes on PET. Change any box.
FIGO 2018 and FIGO 2014 for carcinoma of the cervix. FIGO 2014 stage IA also required horizontal spread of 7 mm or less; the calculator assumes it. The trial line uses KEYNOTE-A18 entry stages and the FDA label; performance status and other entry criteria still apply. The trial excluded nodes above L1 or in the groin, and bilateral hydronephrosis unless drained.
Memory hooks
Tap a card to flip it.
Check yourself
Question 14 mm deep invasion on a cone, margins clear, no visible lesion, PET negative. Stage?
IA2 (over 3 to 5 mm). LVSI on the cone would not change it.
Question 23 cm tumor confined to the cervix; PET shows two avid external iliac nodes, not biopsied. FIGO 2018 and FIGO 2014?
FIGO 2018 IIIC1r. FIGO 2014 IB1, because 2014 ignores nodes. Not eligible for KEYNOTE-A18 and outside the pembrolizumab label.
Question 36 cm tumor into the parametrium, hydronephrosis on the right, no nodes. Stage?
IIIB in both systems: the blocked kidney wins over the parametrium. Inside KEYNOTE-A18 and on the FDA label.
Question 4Cystoscopy shows bullous edema of the bladder; biopsy negative. Tumor 5 cm with parametrial invasion, no nodes. IVA?
No. Bullous edema alone is not IVA. FIGO 2018 IIB, FIGO 2014 IIB. Without nodes, outside KEYNOTE-A18.
Question 5Same IIB patient, but PET shows a para-aortic node, biopsy positive.
FIGO 2018 IIIC2p. FIGO 2014 still IIB, now node positive: inside the KEYNOTE-A18 entry stages if the node is no higher than L1, outside the label. Para-aortic disease also changes the radiation field.
Sources
Retrieved from PubMed and FDA communications, read on Oct 30, 2026.
- Bhatla N, Berek JS, Cuello Fredes M, et al. Revised FIGO staging for carcinoma of the cervix uteri. Int J Gynaecol Obstet 2019;145:129-135. doi:10.1002/ijgo.12749
- Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2025 update. Int J Gynaecol Obstet 2025;171 Suppl 1:87-108. doi:10.1002/ijgo.70277
- Corrigendum to "Revised FIGO staging for carcinoma of the cervix uteri". Int J Gynaecol Obstet 2019;147:279-280 (source of the cut-point wording). doi:10.1002/ijgo.12969
- Pecorelli S. Revised FIGO staging for carcinoma of the vulva, cervix, and endometrium. Int J Gynaecol Obstet 2009;105:103-104. doi:10.1016/j.ijgo.2009.02.012
- FIGO Committee on Gynecologic Oncology. FIGO staging for carcinoma of the vulva, cervix, and corpus uteri. Int J Gynaecol Obstet 2014;125:97-98. doi:10.1016/j.ijgo.2014.02.003
- Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet 2024;403:1341-1350. doi:10.1016/S0140-6736(24)00317-9
KEYNOTE-A18: trial versus label
A woman in her forties has a 6 cm squamous cell carcinoma of the cervix, invading the parametrium, with pelvic nodes on PET. She starts chemoradiation next week. Should pembrolizumab be added, and is it on label?
Concepts first
- Locally advanced
- Too big or too spread in the pelvis for surgery to cure: treated with chemoradiation.
- Chemoradiation
- Weekly cisplatin with external pelvic radiation, then brachytherapy (radiation placed inside the cervix).
- PFS and OS
- Progression-free survival, alive without growth; overall survival, alive.
- HR
- Hazard ratio: under 1 favors pembrolizumab; a confidence interval crossing 1 means no proven difference.
Who got in: 1060 women, 2020 to 2022, 176 centers in 30 countries.Newly diagnosed squamous, adenocarcinoma or adenosquamous carcinoma. FIGO 2014 stage IB2 to IIB with positive nodes, or stage III to IVA with any nodes. A positive node meant a biopsy, or on imaging 2 or more pelvic nodes or 1 para-aortic node (1.5 cm short axis, or PET-avid). Nodes above L1 or in the groin counted as metastatic and excluded. About 56% were stage III to IVA and over 80% were node positive. Stratified by radiation technique, stage and planned radiation dose.
What it did
Read the forest before the headline.The overall result is positive for both endpoints: progression HR 0.70 at the first analysis, death HR 0.67 (0.50 to 0.90) at the second interim analysis (median follow-up 30 months). But in FIGO 2014 IB2 to IIB with nodes, the progression HR was 0.91 (0.63 to 1.31). On January 12, 2024, the FDA approved pembrolizumab with chemoradiation only for FIGO 2014 stage III to IVA. The current label adds the final analysis for that group: death HR 0.65 (0.47 to 0.90).
Age 65 or older
One more subgroup to know.Overall survival point estimates favored pembrolizumab in every prespecified subgroup except women aged 65 or older (HR 1.35 at the second interim analysis, a small group with a wide interval). A point estimate below 1 does not prove benefit in a subgroup. Age is a reason to discuss, not a rule to exclude.
The price
What to watch.Most grade 3 events were blood counts from chemoradiation. Thyroid problems are the immune event you will see most: TSH at baseline and every 6 weeks. Diarrhea during or right after radiation is usually radiation: in the label's stage III to IVA group, 51% with pembrolizumab and 50% with placebo. Test the stool; think colitis if it is severe, bloody, or new or worse once radiation diarrhea should be settling.
Who gets pembrolizumab with chemoradiation?
CALLA and INTERLACE
The other strategies.CALLA, durvalumab with chemoradiation in 770 women, was negative: PFS HR 0.84 (0.65 to 1.08). INTERLACE gave 6 weekly doses of carboplatin AUC 2 and paclitaxel 80 mg/m² before chemoradiation (a median of 7 days after the last dose) in 500 women, including FIGO 2008 IB1 with nodes: 5-year survival 80% versus 72%, HR 0.60. It enrolled from 2012 to 2022, mostly stage IIB. No published phase 3 trial has combined induction chemotherapy with pembrolizumab.
Do not let anything delay the radiation.Finish external beam and brachytherapy within 8 weeks; in retrospective series, totals beyond 9 to 10 weeks meant more pelvic recurrence (FIGO 2025 report). A missed week for a complication is time to make up, not to lose.
Memory hooks
Tap a card to flip it.
Check yourself
Question 1The opening patient: 6 cm, parametrium, pelvic nodes. FIGO 2018, FIGO 2014, and the pembrolizumab question?
FIGO 2018 IIIC1r. FIGO 2014 IIB with nodes: inside the trial if PET showed 2 or more pelvic nodes or one was biopsied, outside the label, in the subgroup where benefit was not shown (HR 0.91). Discuss it; do not present it as standard.
Question 2Tumor reaches the lower third of the vagina, no nodes. Pembrolizumab?
Yes: FIGO 2014 IIIA, on label, in the subgroup with the clearest benefit (HR 0.59).
Question 3Week 8, after radiation ended: watery diarrhea 6 times a day. Radiation enteritis?
Both are possible: radiation diarrhea peaks around now. Send stool tests (including C. difficile) and hold pembrolizumab. If infection is excluded and it does not settle or gets worse, treat as immune colitis (steroids; consider endoscopy).
Question 4A colleague says CALLA proves checkpoint inhibitors do not work with chemoradiation. True?
No. CALLA (durvalumab) missed its PFS endpoint (HR 0.84, interval crossing 1); KEYNOTE-A18 (pembrolizumab) improved both PFS and OS. Different drug, schedule and follow-up; the positive trial sets the standard for FIGO 2014 III to IVA.
Sources
Retrieved from PubMed, FDA communications and the US label, read on Oct 30, 2026.
- Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): a randomised, double-blind, phase 3 clinical trial. Lancet 2024;403:1341-1350. doi:10.1016/S0140-6736(24)00317-9
- Lorusso D, Xiang Y, Hasegawa K, et al. Pembrolizumab or placebo with chemoradiotherapy followed by pembrolizumab or placebo for newly diagnosed, high-risk, locally advanced cervical cancer (ENGOT-cx11/GOG-3047/KEYNOTE-A18): overall survival results from a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 2024;404:1321-1332. doi:10.1016/S0140-6736(24)01808-7
- US Food and Drug Administration. FDA approves pembrolizumab with chemoradiotherapy for FIGO 2014 stage III to IVA cervical cancer, January 12, 2024. fda.gov
- Merck Sharp & Dohme. KEYTRUDA (pembrolizumab) prescribing information, section 14.12, Table 98 (final overall survival, FIGO 2014 III to IVA) and Table 43 (adverse reactions). Revised 7/2026. DailyMed, accessed Oct 30, 2026.
- Monk BJ, Toita T, Wu X, et al. Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA). Lancet Oncol 2023;24:1334-1348. doi:10.1016/S1470-2045(23)00479-5
- McCormack M, Eminowicz G, Gallardo D, et al. Induction chemotherapy followed by standard chemoradiotherapy versus standard chemoradiotherapy alone in patients with locally advanced cervical cancer (GCIG INTERLACE). Lancet 2024;404:1525-1535. doi:10.1016/S0140-6736(24)01438-7
- Bhatla N, Aoki D, Sharma DN, et al. Cancer of the cervix uteri: 2025 update. Int J Gynaecol Obstet 2025;171 Suppl 1:87-108. doi:10.1002/ijgo.70277